Market capitalization | $2.43b |
Enterprise Value | $1.81b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 119.59 |
P/S ratio (TTM) P/S ratio | 160.73 |
P/B ratio (TTM) P/B ratio | 3.70 |
Revenue growth (TTM) Revenue growth | 94.86% |
Revenue (TTM) Revenue | $15.13m |
As a Free StocksGuide user, you can view scores for all 6,900 stocks worldwide.
10 Analysts have issued a Janux Therapeutics Inc forecast:
10 Analysts have issued a Janux Therapeutics Inc forecast:
Jun '24 |
+/-
%
|
||
Revenue | 15 15 |
95%
95%
|
|
Gross Profit | 13 13 |
111%
111%
|
|
EBITDA | -64 -64 |
16%
16%
|
EBIT (Operating Income) EBIT | -66 -66 |
15%
15%
|
Net Profit | -44 -44 |
35%
35%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.
Head office | United States |
CEO | David Campbell |
Employees | 64 |
Founded | 2017 |
Website | www.januxrx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.